Clinical Trials Browser

Tumor Lysis Syndrome × Clear all

Tumor Lysis Syndrome, Hematologic Neoplasms

NCT03098589 2025-03-30

Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

Head & NeckLymphoidOther hematologic neoplasm

Sleepiness, Arrhythmias, Cardiac, Cataract, Confusion, Coronary Artery Disease, Digestive System Diseases, Dizziness, Fatigue, Heart Failure, Hemorrhage, Hypersensitivity, Hypotension, Orthostatic, Hypothyroidism, Infections, Lymphoma, Peripheral Nervous System Diseases, Seizures, Thromboembolism, Tumor Lysis Syndrome, Neoplasms, Second Primary, Lung Diseases, Interstitial, Renal Insufficiency, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Teratogenesis

NCT03406156 2024-08-06

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Phase 3 Completed

120 enrolled 14 charts

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Neoplasms, Tumor Lysis Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04214093 2023-08-02

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

Phase 1 Terminated

9 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Recurrence, Tumor Lysis Syndrome, Hematologic Neoplasms

NCT05840289 2023-05-06

FRILLY

Unknown

94 enrolled

Tumor Lysis Syndrome

NCT02921828 2022-07-05

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

Completed

1,149 enrolled

GenitourinaryPlasma cell

Sleepiness, Arrhythmias, Cardiac, Confusion, Consciousness Disorders, Dizziness, Fatigue, Heart Failure, Hypersensitivity, Infections, Jaundice, Liver Diseases, Multiple Myeloma, Peripheral Nervous System Diseases, Thromboembolism, Tumor Lysis Syndrome, Lung Diseases, Interstitial, Acute Kidney Injury, Teratogenesis

NCT02921802 2022-06-14

A Study of Special Use Results Surveillance of Revlimid 5mg Capsules

Completed

4,626 enrolled

Classical hematologyMyeloidOtherPlasma cell

Arrhythmias, Cardiac, Constipation, Diarrhea, Heart Failure, Hemorrhage, Hypersensitivity, Infections, Multiple Myeloma, Myelodysplastic Syndromes, Myocardial Infarction, Neutropenia, Peripheral Nervous System Diseases, Thrombocytopenia, Tumor Lysis Syndrome, Lung Diseases, Interstitial, Renal Insufficiency, Venous Thromboembolism, Teratogenesis

NCT02922543 2022-06-14

A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use

Completed

361 enrolled

Classical hematologyOtherPlasma cell

Arrhythmias, Cardiac, Constipation, Diarrhea, Heart Failure, Hemorrhage, Hypersensitivity, Infections, Multiple Myeloma, Myocardial Infarction, Neutropenia, Peripheral Nervous System Diseases, Thrombocytopenia, Tumor Lysis Syndrome, Lung Diseases, Interstitial, Renal Insufficiency, Venous Thromboembolism, Teratogenesis

NCT01200485 2020-01-31

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

Phase 2 Completed

55 enrolled 11 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Tumor Lysis Syndrome, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT00445341 2018-01-30

Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma

Phase 1/2 Completed

28 enrolled 10 charts

Lymphoid

Lymphoma, Tumor Lysis Syndrome, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT01724528 2014-11-03

FLORENCE

Phase 3 Completed

346 enrolled 16 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Tumor Lysis Syndrome

NCT00628628 2013-08-01

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

Phase 2 Completed

82 enrolled 6 charts

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Tumor Lysis Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hyperuricemia

NCT01097369 2013-01-31

Elitek (Rasburicase) Immuno-Monitoring Study

Terminated

1 enrolled

Tumor Lysis Syndrome

NCT00360438 2012-08-01

Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS

Phase 1/2 Completed

18 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Tumor Lysis Syndrome

NCT00230178 2010-01-12

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Phase 3 Completed

280 enrolled 10 charts

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasms, Tumor Lysis Syndrome, Hyperuricemia

NCT00230217 2009-03-30

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

Phase 4 Completed

94 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Neoplasms, Recurrence, Tumor Lysis Syndrome, Hyperuricemia

NCT00651911 2008-04-03

Fasturtec TLS Treatment / Prophylysis

Phase 4 Completed

45 enrolled

Tumor Lysis Syndrome

Clinical Trials

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

FRILLY

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

A Study of Special Use Results Surveillance of Revlimid 5mg Capsules

A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma

FLORENCE

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

Elitek (Rasburicase) Immuno-Monitoring Study

Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

Fasturtec TLS Treatment / Prophylysis